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IMPORTANCE An improvedmodel for risk stratification can be useful for guiding public health
strategies of breast cancer prevention.
OBJECTIVE To evaluate combined risk stratification utility of common low penetrant single
nucleotide polymorphisms (SNPs) and epidemiologic risk factors.
DESIGN, SETTING, AND PARTICIPANTS Using a total of 17 171 cases and 19 862 controls sampled
from the Breast and Prostate Cancer Cohort Consortium (BPC3) and 5879women
participating in the 2010 National Health Interview Survey, a model for predicting absolute
risk of breast cancer was developed combining information on individual level data on
epidemiologic risk factors and 24 genotyped SNPs from prospective cohort studies,
published estimate of odds ratios for 68 additional SNPs, population incidence rate from the
National Cancer Institute-Surveillance, Epidemiology, and End Results Program cancer
registry and data on risk factor distribution from nationally representative health survey. The
model is used to project the distribution of absolute risk for the population of white women in
the United States after adjustment for competing cause of mortality.
EXPOSURES Single nucleotide polymorphisms, family history, anthropometric factors,
menstrual and/or reproductive factors, and lifestyle factors.
MAIN OUTCOMES ANDMEASURES Degree of stratification of absolute risk owing to
nonmodifiable (SNPs, family history, height, and some components of menstrual and/or
reproductive history) andmodifiable factors (bodymass index [BMI; calculated as weight in
kilograms divided by height in meters squared], menopausal hormone therapy [MHT],
alcohol, and smoking).
RESULTS The average absolute risk for a 30-year-old white woman in the United States
developing invasive breast cancer by age 80 years is 11.3%. Amodel that includes all risk
factors provided a range of average absolute risk from 4.4% to 23.5% for women in the
bottom and top deciles of the risk distribution, respectively. For womenwhowere at the
lowest and highest deciles of nonmodifiable risks, the 5th and 95th percentile range of the
risk distribution associated with 4modifiable factors was 2.9% to 5.0% and 15.5% to 25.0%,
respectively. For women in the highest decile of risk owing to nonmodifiable factors, those
who had low BMI, did not drink or smoke, and did not use MHT had risks comparable to an
average woman in the general population.
CONCLUSIONS AND RELEVANCE This model for absolute risk of breast cancer including SNPs
can provide stratification for the population of white women in the United States. Themodel
can also identify subsets of the population at an elevated risk that would benefit most from
risk-reduction strategies based on altering modifiable factors. The effectiveness of this model
for individual risk communication needs further investigation.
JAMA Oncol. 2016;2(10):1295-1302. doi:10.1001/jamaoncol.2016.1025
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B reast cancer remains themost common form of cancerdiagnosedinwomenindevelopedcountriesof theWest-ern world, with an estimated 232670 new cases diag-
nosedin2014intheUnitedStatesalone.1Theincidenceofbreast
cancer is also reported to be rapidly rising in a number of de-
velopingcountries,possiblyowing to thecongruenceofanum-
ber of factors, including changes in lifestyle, behavioral pat-
terns, and improved diagnostics, all results of economic
growth.2,3 Decades of epidemiologic research have led to the
identificationofanumberof lifestyleandenvironmentalbreast
cancerriskfactors, includingmenstrualand/orreproductivehis-
tory, use of hormones, anthropometry, and alcohol consump-
tion,eachtypicallyexplainingamodestproportionof thevaria-
tion indiseaserisk.4,5However,whencombined, theknownrisk
factorscouldhaveasubstantialeffectonbreastcancerrisk.More
recently, genome-wide association studies (GWAS) have led to
the identification of 92 common susceptibility loci marked by
singlenucleotidepolymorphisms(SNPs).6-8TheseSNPsareeach
associated with only a small effect size but cumulatively ex-
plain substantial variation in risk.9,10 The proportion of varia-
tion in risk explained by common genetic variation is likely to
increase in thenear future, after thecompletionof theOncoAr-
ray project11 that is anticipated to detectmany additional risk-
associated variants for breast cancer.
AsGWASarerapidlyexpandingthespectrumofgenetic risk
factors forbreast cancer, it is timely toevaluatehowsuch infor-
mationcanbeusedtounderstandthedistributionofbreastcan-
cer risk across populations and focus strategies for cancer
prevention.10,12,13 Following the discoveries from early GWAS,
several studies14-17havereportedonlymodestutilityofSNPs for
improvingthediscriminatoryaccuracyofbreastcancer riskpre-
dictionmodels. However, a recent study9 followingnumerous
discoveries from the large Collaborative Oncological Gene-
environmentStudy(COGS)project indicatedthatapolygenicrisk
score (PRS)definedbythecombinationof77SNPscouldbeuse-
ful forprovidingsubstantial riskstratificationof thepopulation.
AsSNPsandcertainother risk factorsarenonmodifiable (ie, risk
factors that cannot bemodified or are unlikely to bemodified
with the purpose of altering breast cancer risk), it is unclear
whetherandhowinformationon thesenonmodifiable risk fac-
tors canguideprimarycancerpreventionefforts that intervene
onmodifiable risk factors. Ina recent commentary,10weuseda
syntheticmodel,basedonpublishedestimatesofriskparameters
and theassumptionofmultiplicativegene-environment inter-
action, to show that a PRSdefined by knownSNPs canprovide
risk stratification toadegree thatmaybeuseful forprevention.
For instance, it couldbehelpful inassessing individualizedrisk-
benefittradeoffsassociatedwiththeuseofmenopausalhormone
therapy (MHT) and endocrine-based prevention strategies.
Thegoal of this studywas tousedata fromprospective co-
hort studiesparticipating in theBreast andProstateCancerCo-
hortConsortium(BPC3)18,19 todevelopamoreempiricalmodel
for predicting absolute risk of invasive breast cancer. This
modelwas thenused toproject thedistributionsof risk for the
general population of white women in the United States, de-
composed into modifiable and nonmodifiable risk compo-
nents. We provide estimates of the number of breast cancers
thatwould bepreventable through risk factormodification in
strata of the population at different levels of risk from non-
modifiable factors.Results fromtheseprojectionsprovidenew
insight into thechallengesandopportunities for risk-based tar-
geted primary cancer prevention efforts.
Methods
Study Population
TheBPC3haspreviously beendescribed indetail.19-21 In short,
it consists of 8 large, prospective cohorts fromEurope, Austra-
lia, and the United States with genetic data and questionnaire
information. The diagnosis of cases of breast cancer was con-
firmedbymedical recordsand/or tumorregistries.Analysespre-
sented in this manuscript include only invasive breast cancer
cases. We analyzed data available from the nested case-
control samples within the cohorts selected for genetic stud-
ies. In these studies, subjectswere consideredeligible controls
if they were free of breast cancer until the diagnosis of breast
cancer in the matched case subject. Matching criteria varied
amongcohorts,butageandmenopausal statusatbaselinewere
used forall. TheBPC3projectwasapprovedby theethical com-
mitteeoftheInternationalAgencyforResearchonCancer(IARC)
for the EPIC cohort, by the Emory University Institutional Re-
viewBoard forCPS-II cohort, by the InstitutionalReviewBoard
of theUniversity ofHawaii andUniversity of SouthernCalifor-
nia for theMECcohort,by theethical committeeof theBrigham
andWomen’s Hospital for the NHS cohort and theNCI Institu-
tional Review Board for the PLCO cohort.
The BPC3 study and published estimates of SNP odds ra-
tios (ORs)wereused todevelopa logistic regressionmodel that
included a polygenic risk score (PRS), nonmodifiable risk fac-
torsother than thePRS (ie, familyhistory, ageat first birth,par-
ity, age at menarche, height, menopausal status, and age at
menopause), alongwithmodifiable risk factors (ie, bodymass
index [BMI; calculatedasweight inkilogramsdividedbyheight
inmeterssquared],MHTuse, levelofalcoholconsumption,and
smoking status). The eMethods in the Supplement describe in
detail all steps in the development of this model, which in-
cludes 92 known susceptibility SNPs (eTable 2 in the Supple-
ment) and theother risk factors.Data on24SNPsgenotyped in
Key Points
Questions What is the utility of low penetrant common single
nucleotide polymorphisms (SNPs) for guiding public health
strategies for breast cancer prevention?
Findings A risk predictionmodel including 92 susceptibility SNPs
and various epidemiologic risk factors can provide important
stratification for absolute risk for white women in the United
States. Themodel predicts that effect of healthy lifestyle choices
for risk reduction is expected to be larger for womenwho are at
higher risk owing to genetic susceptibility and other nonmodifiable
risk factors.
Meaning The assessment of common SNPsmay be useful for
screening recommendations and individualized risk
communication.
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subjects in theBPC3was initiallyused toderiveapolygenic risk
score for the 24 SNPs (PRS-24) by assuming additive associa-
tionsonthe logscaleof theSNPs inthe logistic regressionmodel
after adjustment for study, age at study entry, and family his-
tory.Dataon the24genotypedSNPswasused toevaluatemul-
tiplicative interactions between individual SNPs and PRS-24
with other risk factors.We also used a recently developed tail-
based χ2 goodness of fit test22 to assess possible deviations of
risks estimated from amultiplicative model from true risks at
the extremes of the risk distribution. Assuming the validity of
themultiplicativemodel,we thenderivedamodelbasedonall
92knownbreast cancerSNPs (PRS-92)basedonpublishedORs
for the 68 remaining SNPs that were not genotyped in BPC3.
Absolute RiskModeling
Webuilt amodel for absolute risk of invasive breast cancer for
thepopulationofwhitewomen in theUnitedStatesbycombin-
ingestimatesofORparametersobtained fromtheBPC3andex-
ternal GWAS studies, age-specific breast cancer rates from the
USNationalCancerInstitute-Surveillance,Epidemiology,andEnd
ResultsProgram(NCI-SEER)anddataoncompetinghazards for
mortality available from the Center for Disease Control (CDC)
WONDERdatabase23 (eMethods in the Supplement).
Projection of Absolute Risk Distribution for the Population
ofWhiteWomen in the United States
Weprojectedthedistributionofabsolute risk for thepopulation
ofwhitewomen in the United States based on the distribution
of risk factorsobserved innationally representativesurveydata
fromtheNationalHealth InterviewSurveyandNationalHealth
andNutritionExaminationSurvey.24-28Weassumedthatriskfac-
tors andPRS-92 are independently distributed, conditional on
familyhistory.Wethengenerated thedistributionofPRSbased
on normal distribution theory (eMethods in the Supplement).
We further assessed thedistributionof riskowing tomodi-
fiable risk factors (BMI,MHTuse, alcohol, smoking) in catego-
riesdefinedby risk fromnonmodifiable factors, includingPRS-
92.Weestimated theproportionof breast cancer that couldbe
preventedby shifting thewholepopulation to the lowest level
ofmodifiableriskwithineachstrataof thepopulationasdefined
bythenonmodifiableriskfactors (eMethodsintheSupplement).
Results
Theanalysis involveda total numberof 17 171 cases and 19862
controls from8prospective cohort studies, but thenumber of
cases and controls with complete information in each study
varied by risk factor (eTable 1 in the Supplement).
Assessment of Interactions and RiskModel Building
The additivemodel on the logistic scale for the SNP-risk asso-
ciations in the PRS-24 risk model was adequate, even at the
extremes of risk. Consistently, estimates of the ORs associ-
atedwithdecilesofa fitted logistic regressionmodel forPRS-24
and familyhistoryclosely followedtheirvaluespredicted from
the normal distribution theory for PRS (eMethods and eTable
3 in the Supplement).
Odds ratio estimates for individual risk factors from the
fittedmultivariate logistic regressionmodel are shown ineFig-
ure 1 in the Supplement. The association between risk and
quantitative factors (height, number of children, age at first
birth, and alcohol use) appeared to be nonlinear on the logis-
tic scale; thus, in subsequent analysis, wemodeled quantita-
tive factors as categorical variables, defined by the deciles of
their distributions in controls (eMethods and eTable 4 in the
Supplement). Higher BMI was associated with increased risk
only for postmenopausal women, and the strength of the as-
sociationwas stronger forpatientswhodidnotuseMHT(eFig-
ure 1 in the Supplement). We did not detect any statistically
significant interactionsbetweenPRS-24and individual risk fac-
tors in the categorical or the continuous modeling ap-
proaches (data not shown). We also performed an overall χ2
goodness-of-fit test for thismodelusinga tail-basedmethod22
and found that themodel including both PRS-24 and all other
risk factors in a multiplicative fashion (or additive in the lo-
gistic scale) fit the BPC3 data adequately.
The final risk model included main effects of the PRS-92
(genotypedPRS-24plus simulatedPRS-68, asdescribed inour
Methods section), main effects of all of the risk factors coded
ascategorical variables, and interaction terms involvingmeno-
pausal status,BMI,andMHTvariables (eMethods intheSupple-
ment). The area under the receiver operating curve (AUC) for
modelswith only questionnaire-based risk factors, only PRS-
92, andboth typesof risk factorswere0.588,0.623, and0.648,
respectively (eFigure 2 in the Supplement).
Stratification of Absolute Breast Cancer Risk
Although AUC values were low to modest, the models, par-
ticularly themodels including thePRS, led tosubstantial spread
in the distribution of absolute risk for the population. For ex-
ample, the absolute cumulative risk of a 30-year-old white
woman in the United States developing invasive breast can-
cer over the next 50 years is 11.3% on average. Amodel based
on PRS-92 and questionnaire-based risk factors could iden-
tify 5%of thepopulationwith risk below4.5%or above22.0%
Figure 1. Projected Distribution of Absolute Lifetime Risk of Breast
Cancer forWhiteWomen in the United States Ages 30 to 80 Years
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(Figure 1). As risk accumulated over age, the degree of strati-
fication of absolute risk provided by all the risk factors com-
binedalso increasedwith age (Figure2). Thepercentageof the
population that couldbe identified tobeofmoderate risk (two-
fold to 3-fold risk comparedwith the population average) and
high risk (>3-fold risk comparedwith the population average)
variedsubstantiallyamongmodels (Table 1),with themostpro-
nounceddiscriminationfor the fullmodelcomparedwithmod-
els with only PRS-based or questionnaire-based risk factors.
Distribution ofModifiable and Nonmodifiable
Breast Cancer Risk
The spread in the distribution of risk by the 4modifiable risk
factors (ie, BMI,MHTuse, alcohol use, smoking)was larger for
those substrata of the population that were at higher risk ow-
ing to nonmodifiable risk factors (Figure 3). For example, the
5th and 95th percentile ranges of the risk distribution associ-
ated with modifiable factors were 2.9% to 5.0% and 15.5 to
25.0% for subjectswhowere in the lowest andhighest deciles
of nonmodifiable risk, respectively. Accordingly, estimates of
the proportion of cases that could be prevented by the reduc-
tionofmodifiable risksvariedsubstantially across these strata,
with ahigher proportion of preventable cases in the strata de-
fined by higher nonmodifiable risks (Table 2). In our model,
wedefinedwomenat the lowest risk frommodifiable risk fac-
tors as thosewhowere in the lowest decile of BMI, didnot use
MHT,didnotdrinkalcohol, anddidnot smoke.Overall,wees-
timated that up to 28.9% of all breast cancers could be pre-
vented if allwhitewomen in theUSpopulationwereat the low-
est risk from these 4 modifiable risk factors. Nearly one-fifth
of these total preventable cases arise from the subpopulation
in the topdecile of nonmodifiable risk. In contrast, only about
4% of the preventable cases arise from the population in the
lowest decile of nonmodifiable risk.
Discussion
Utilizing amodel includingmost known risk factors for breast
cancer, we have shown that this information can be used to
identifywhitewomen in theUSpopulationat substantiallydif-
ferent levelsofabsolute risk for invasivebreast cancer.Wehave
also shown that the benefit (in terms of reductions in abso-
lute risk) this population could achieve by changing modifi-
able risk factors is expected to be larger for those who are at
higher than lower risk fromnonmodifiable factors. This indi-
Table 1. Total Number of At-Risk Subjects and Incident Cases Expected at Different Risk Levels for Every 100000WomenWith Assessed Risk
Risk Level
Model
PRS-92 Only Questionnaire-Based Risk Factors Only PRS-92 and Risk Factors
Total Subjects, No. Cases, No. Total Subjects, No. Cases, No. Total Subjects, No. Cases, No.
Moderate risk: RR = 2-3a 2691 688 306 74 4116 1076
High risk: RR>3a 109 40 0 0 649 181
10-y risk at 40 is > average
10-y risk at 50b
9113 295 6531 194 16 134 564
10-y risk at 50 is < average
10-y risk at 40c
27 018 380 11 231 184 32 037 425
Abbreviations: PRS, polygenic risk score; PRS-92, all 92 known breast cancer
SNPs; RR, relative risk; SNP, single nucleotide polymorphisms.
a The reference is 11.3%, the average risk in women ages 30 to 80 years.
b The average 10-y risk at age 50 years is 2.6%.
c The average 10-y risk at age 40 years is 1.8%.
Figure 2. Cumulative and 10-Year Breast Cancer Risk forWhiteWomen in the United States Stratified by Risk Percentiles
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cates that individual informationonriskcouldbeuseful inmak-
ing more informed decisions on breast cancer prevention.
Our results are generally consistent with the theoretical
projections made regarding the degree of risk stratification
achievable for variousbreast cancer riskmodels under anum-
ber of assumptions, including multiplicative effects of ge-
netic and other risk factors.10 Like other recent large
studies,18,19,21,29-32 we did not detect any evidence of multi-
plicative interactions between lifestyle and/or environmen-
tal risk factors and SNPs. Moreover, by application of a novel
χ2 goodness-of-fit test22 designed to detect model misspeci-
fication at extremes of disease risk, our analysis provides ad-
ditional evidence that a multiplicative model for gene-
environment interactions is adequate for describing the joint
risk of breast cancer forwomenwith different risk factor pro-
files. This was shown for the 24 SNPs that were genotyped in
our sample.We couldnot validate themultiplicative assump-
tion of the model for the full set of 92 SNPs owing to the lack
of genotyped data on 68 SNPs. However, our analyses of 24
SNPs and other very large, previously published
studies18,19,21,29-32 including more SNPs provide solid sup-
port for themultiplicativemodel.Multiplicative effects across
many risk factors, even when individual effects are modest,
can lead topronouncedstratification for absolute riskofbreast
cancer, as described in this report. The multiplicative model
also implies that the absolute risk difference frommodifiable
risk factors varies by levels of nonmodifiable risk factors.33
The US Preventive Services Task Force currently recom-
mends biennial screeningmammography forwomen ages 50
to74years andconsiderationof individual factors, suchas risk
andpotential benefit, for thedecision to start screeningmam-
mography prior to age 50 years. Our analysis shows that use
of a model based on most known risk factors can change the
recommendation for screening for a substantial fractionof the
population, compared with using only age-based criteria
(Table 1). For example, a full model based on PRS and other
risk factors can identify 16.1% of the population who can be
Figure 3. Distribution of Absolute Lifetime Risk Associated
WithModifiable Risk Factors Stratified by Deciles of Nonmodifiable
Risk forWhiteWomen in the United States
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Table 2. Estimates of Proportion of Breast Cancer Cases Preventable by Reduction ofModifiable Risk in Different Strata
of the Population Defined by Nonmodifiable Risk Factorsa
Nonmodifiable Risk Groups
Proportion of Breast Cancer, %
Alcohol MHT BMIb Smoking
All 4 Modifiable Risk Factors
Simultaneouslyc
P T P T P T P T P T
Decile
1 4.00 0.36 4.60 0.31 4.80 0.57 4.10 0.12 4.40 1.28
2 5.50 0.49 5.80 0.38 6.30 0.76 5.70 0.17 5.90 1.70
3 6.60 0.59 7.00 0.47 7.20 0.87 6.80 0.21 7.00 2.01
4 7.70 0.69 8.30 0.55 8.10 0.98 7.90 0.24 8.00 2.31
5 8.60 0.77 8.80 0.58 9.10 1.09 8.70 0.27 8.80 2.55
6 9.90 0.89 9.50 0.63 10.10 1.22 9.60 0.30 9.80 2.84
7 11.10 1.00 11.10 0.74 10.90 1.32 10.80 0.33 11.00 3.18
8 12.40 1.11 12.00 0.80 12.10 1.46 12.50 0.38 12.20 3.53
9 14.70 1.32 14.30 0.95 13.80 1.66 15.20 0.47 14.30 4.14
10 19.7 1.78 18.50 1.23 17.50 2.11 18.80 0.58 18.50 5.35
PARd – 9.01 – 6.64 – 12.05 – 3.08 – 28.90
Abbreviations: BMI, bodymass index; MHT, menopausal hormone therapy;
P, total number of preventable breast cancers; PAR, population-attributable
risk; T, total number of breast cancers.
a The proportions for each stratum are shown relative to the total number of
breast cancers (%T) and total number of preventable breast cancers (%P) that
are expected to arise in the whole population.
bBMI is calculated as weight in kilograms divided by height in meters squared.
c Themodifiable risk factors are bodymass index, MHT use, alcohol use, and
smoking.
d Estimate of population-attributable risk due tomodifiable factors (individually
and simultaneously). PAR is given by column sum of T and%P = (%T/PAR)
× 100 .
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recommended to start screening at age 40 years as their 10-
year risk exceeds that of an average 50-year-oldwoman.How-
ever, the number of additional cases that would be detect-
able by screening would still be low, as a percentage of the
womenforwhomriskneeds tobeassessed, and thus thepopu-
lation-level benefit of such practice, would depend on the
implementation cost of risk assessment. The full model can
also identify 32.0%of thepopulationwhoat age50yearshave
10-year risk less than that of an average 40-year-old woman.
These women benefit least from screening and may benefit
from additional counseling about risk of false-positive
results.
Results fromtheseanalysescouldhave implications for fu-
ture cancer prevention efforts, particularly for risk communi-
cation and counseling at an individual level. For instance,
women found to be at elevated risk owing to factors that can-
notbe changedmaybemoremotivated toadopt ahealthy life-
style to lower their risk of breast cancer if they had a better
understanding of the potential gains. In this regard, it is en-
couraging that even for women in the highest decile of risk
owing to nonmodifiable factors, those who had low BMI, did
not smoke or drink, and did not use MHT, had risks compa-
rable to those for an average woman in the general popula-
tion. Further research is needed to evaluate how knowledge
of individual risk can influence behavior to modify risk.34,35
Early studies36-39 that have evaluated whether knowledge of
genetic risk can improve health behavior have shown mixed
results. As the number of susceptibilitymarkers and their cu-
mulative power to identify risk continue to increase formany
common diseases, it will be increasingly important to de-
velopandevaluateeffective riskcommunicationstrategies that
may motivate adoption of healthy behavior.
Consistent with a previous report from the United
Kingdom,4 our analysis indicates that only a modest propor-
tion (29%)of breast cancer cases could bepreventedbymodi-
fying most known risk factors. We also showed that a larger
fraction of the total preventable cases would occur among
womenathigher levels of riskowing togenetic risk factors and
other nonmodifiable risk factors. This could indicate that cer-
tain interventions for risk factormodification thatmaynot be
applicable to the whole population because of cost and other
considerations could be targeted to high-risk strata to obtain
ahigher yield of cancers prevented.Asnotedbefore, the cost-
benefit ratio of such targeted interventionwill depend on the
cost of implementing risk assessment. However, a substan-
tial proportion of cases preventable by modification of risk
factors is still expected to arise outside the high-risk strata.
Therefore, to have a major effect on reducing the disease
burden, broader efforts for preventionneed to continue at the
population level. Furthermore, although these epidemio-
logic estimates of preventable cases could be auseful guide to
understanding the potential effect of intervention and life-
style change, ultimately evidence from randomized trialswill
be needed tounderstand the true effect of an intervention for
the underlying population, as a whole or for subgroups.
Nonmodifiable risk factorsweredefinedas those that can-
not bemodified (eg, genetics) or that are unlikely to bemodi-
fiedwith theaimof reducingbreast cancer risk.However, some
of these factors do have modifiable components (height, age
at menarche, and age at menopause are partially determined
bydietandbodysize).A limitationof this report is thatwecould
not evaluate several known risk factors for breast cancer since
datawerenotavailable in theBPC3dataset.These include level
of education, breastfeeding, physical activity, breast condi-
tions (such as mammographic density and benign breast dis-
ease), and endogenous hormone biomarkers (such as estra-
diol, testosterone, and prolactin levels).40 Further model
improvements could also be achieved by refining the risk fac-
tors included inthemodel (eg, changes inBMIsinceage18years
rather than current BMI). Our risk projections accounted for
expected changes in MHT use over time based on the popu-
lation distribution of length of use. However, our model as-
sumed that all other risk factors remained constant over the
timeperiodof projected risk. Thus, theproportionof prevent-
able cases including all known modifiable risk factors could
be larger than reported here.
As information on all risk factors was not available in a
single large study, we developed themodel using a combina-
tionof imputation (for risk factors thatwere available inBPC3
but hadmissingdata) and simulation (for PRS associatedwith
68 SNPs not genotyped in BPC3). Use of imputation within
BPC3 allowed us to obtain more precise estimates of model
parameters than those that could be obtained had we ana-
lyzed patients with only complete data. Nevertheless, when
additional variation due to imputation was accounted for,
substantial uncertainty in estimates of OR parameters was
observed for several risk factors (eFigure 1 in the Supple-
ment). In contrast, the use of simulation for 68 SNPs allowed
us to incorporate information on very precise estimates of
the OR parameters that are available from much larger case-
control studies. In principle, risk estimates can be biased
owing to the violation of the underlying assumption of mul-
tiplicative effect of SNPs and other risk factors, but for rea-
sons noted earlier herein, this scenario is unlikely. As inci-
dence density sampling was not followed in all studies, it is
also possible that there could be some bias due to the use of
ORs toestimate thehazard ratioparametersunderlying theab-
solute risk model (eMethods in the Supplement). The effects
ofdifferent typesofbiasesowing tovariousmodelingassump-
tions need to be examined in future validation studies.
Our analysis also has several strengths, including the
developmentof amodel for relative risksbasedona large case-
control sample drawn from prospective cohort studies, the
incorporationof informationoncancer rate and risk factordis-
tributions from nationally representative databases, and the
use of novel methodologic framework for assessment of risk
stratification. Future studies are needed to evaluate the value
of incorporatingadditional informationonfactors intoamodel.
Although our model assumptions are supported by analyses
of very large sets of data, this model, as well as future exten-
sions (eg, including more SNPs and other risk factors), need
to be validated in independent prospective cohort studies. A
morepreciseestimateof riskparameters associatedwith some
of the epidemiologic risk factors could be used to reduce un-
certainty in the estimates of risk that are produced by the
model.
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Conclusions
Our results illustrate the potential value of risk stratification
to improve breast cancer prevention, particularly to aid
decisions on risk factor modification at the individual
level. The effect of such models for improving the
cost-benefit ratio of population-based prevention pro-
grams will depend on the implementation cost of risk
assessment.
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